Patient, disease, and transplantation characteristics
| Characteristic . | MSD age ≥50 y . | MUD age <50 y . | P . |
|---|---|---|---|
| No. of patients | 1415 | 757 | |
| No. of transplant centers | 176 | 90 | |
| Age, y | .87 | ||
| 50-59 | 1020 (72) | 552 (73) | |
| 60-69 | 374 (26) | 193 (25) | |
| 70-75 | 21 (1) | 12 (2) | |
| Male sex | 846 (60) | 455 (60) | .89 |
| Performance score | <.001 | ||
| 90-100 | 888 (63) | 442 (58) | |
| ≤80 | 480 (34) | 223 (29) | |
| Not reported | 47 (3) | 92 (12) | |
| Disease | .006 | ||
| Acute myeloid leukemia | 571 (40) | 333 (44) | |
| Acute lymphoblastic leukemia | 86 (6) | 63 (8) | |
| Chronic myeloid leukemia | 239 (17) | 91 (12) | |
| Myelodysplastic syndrome | 166 (12) | 98 (13) | |
| Non-Hodgkin lymphoma | 238 (17) | 108 (14) | |
| Chronic lymphocytic leukemia | 115 (8) | 64 (8) | |
| Disease status at transplantation | .010 | ||
| Remission/chronic phase | 736 (52) | 351 (46) | |
| Relapse/blast phase | 679 (48) | 406 (54) | |
| Interval from diagnosis to transplantation, mo | .005 | ||
| <6 | 455 (32) | 186 (25) | |
| 6-12 | 327 (23) | 211 (28) | |
| 13-18 | 163 (12) | 91 (12) | |
| 19-24 | 90 (6) | 55 (7) | |
| >24 | 380 (27) | 214 (28) | |
| Conditioning regimen | .33 | ||
| Myeloablative conditioning | 701 (50) | 356 (47) | |
| Reduced intensity conditioning | 714 (50) | 401 (53) | |
| In vivo T-cell depletion | <.001 | ||
| Yes | 278 (20) | 218 (29) | |
| No | 1137 (80) | 539 (71) | |
| GVHD prophylaxis | <.001 | ||
| Tacrolimus-containing | 345 (24) | 434 (57) | |
| Cyclosporine-containing | 1070 (76) | 323 (43) | |
| Graft type | <.001 | ||
| Bone marrow | 254 (18) | 297 (39) | |
| Peripheral blood progenitor cells | 1161 (82) | 460 (61) | |
| Donor-recipient sex match | <.001 | ||
| Female donor, male recipient | 371 (26) | 118 (16) | |
| Others | 1044 (74) | 639 (84) | |
| Donor-recipient CMV serostatus | <.001 | ||
| Donor and recipient negative | 274 (19) | 232 (31) | |
| Donor and/or recipient positive | 1141 (81) | 525 (69) | |
| Donor age, y | <.001 | ||
| Median (range) | 58 (50-85) | 34 (19-49) | |
| 19-29 | __ | 256 (34) | |
| 30-39 | __ | 306 (40) | |
| 40-49 | __ | 195 (26) | |
| 50-59 | 882 (62) | __ | |
| 60-69 | 464 (33) | __ | |
| ≥70 | 69 (5) | __ | |
| Year of transplantation | <.001 | ||
| 1995-1999 | 383 (27) | 99 (13) | |
| 2000-2005 | 1032 (73) | 658 (87) | |
| Median follow-up (range), mo | 56 (3-156) | 49 (12-145) |
| Characteristic . | MSD age ≥50 y . | MUD age <50 y . | P . |
|---|---|---|---|
| No. of patients | 1415 | 757 | |
| No. of transplant centers | 176 | 90 | |
| Age, y | .87 | ||
| 50-59 | 1020 (72) | 552 (73) | |
| 60-69 | 374 (26) | 193 (25) | |
| 70-75 | 21 (1) | 12 (2) | |
| Male sex | 846 (60) | 455 (60) | .89 |
| Performance score | <.001 | ||
| 90-100 | 888 (63) | 442 (58) | |
| ≤80 | 480 (34) | 223 (29) | |
| Not reported | 47 (3) | 92 (12) | |
| Disease | .006 | ||
| Acute myeloid leukemia | 571 (40) | 333 (44) | |
| Acute lymphoblastic leukemia | 86 (6) | 63 (8) | |
| Chronic myeloid leukemia | 239 (17) | 91 (12) | |
| Myelodysplastic syndrome | 166 (12) | 98 (13) | |
| Non-Hodgkin lymphoma | 238 (17) | 108 (14) | |
| Chronic lymphocytic leukemia | 115 (8) | 64 (8) | |
| Disease status at transplantation | .010 | ||
| Remission/chronic phase | 736 (52) | 351 (46) | |
| Relapse/blast phase | 679 (48) | 406 (54) | |
| Interval from diagnosis to transplantation, mo | .005 | ||
| <6 | 455 (32) | 186 (25) | |
| 6-12 | 327 (23) | 211 (28) | |
| 13-18 | 163 (12) | 91 (12) | |
| 19-24 | 90 (6) | 55 (7) | |
| >24 | 380 (27) | 214 (28) | |
| Conditioning regimen | .33 | ||
| Myeloablative conditioning | 701 (50) | 356 (47) | |
| Reduced intensity conditioning | 714 (50) | 401 (53) | |
| In vivo T-cell depletion | <.001 | ||
| Yes | 278 (20) | 218 (29) | |
| No | 1137 (80) | 539 (71) | |
| GVHD prophylaxis | <.001 | ||
| Tacrolimus-containing | 345 (24) | 434 (57) | |
| Cyclosporine-containing | 1070 (76) | 323 (43) | |
| Graft type | <.001 | ||
| Bone marrow | 254 (18) | 297 (39) | |
| Peripheral blood progenitor cells | 1161 (82) | 460 (61) | |
| Donor-recipient sex match | <.001 | ||
| Female donor, male recipient | 371 (26) | 118 (16) | |
| Others | 1044 (74) | 639 (84) | |
| Donor-recipient CMV serostatus | <.001 | ||
| Donor and recipient negative | 274 (19) | 232 (31) | |
| Donor and/or recipient positive | 1141 (81) | 525 (69) | |
| Donor age, y | <.001 | ||
| Median (range) | 58 (50-85) | 34 (19-49) | |
| 19-29 | __ | 256 (34) | |
| 30-39 | __ | 306 (40) | |
| 40-49 | __ | 195 (26) | |
| 50-59 | 882 (62) | __ | |
| 60-69 | 464 (33) | __ | |
| ≥70 | 69 (5) | __ | |
| Year of transplantation | <.001 | ||
| 1995-1999 | 383 (27) | 99 (13) | |
| 2000-2005 | 1032 (73) | 658 (87) | |
| Median follow-up (range), mo | 56 (3-156) | 49 (12-145) |
Data are expressed as n (%), unless otherwise indicated.
CMV, cytomegalovirus.